1. Home
  2. NFGC vs ABUS Comparison

NFGC vs ABUS Comparison

Compare NFGC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Found Gold Corp

NFGC

New Found Gold Corp

HOLD

Current Price

$2.18

Market Cap

928.8M

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.33

Market Cap

929.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NFGC
ABUS
Founded
2016
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
928.8M
929.6M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
NFGC
ABUS
Price
$2.18
$4.33
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
1.7M
1.9M
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
N/A
N/A
Revenue
N/A
$14,083,000.00
Revenue This Year
$3,542.00
N/A
Revenue Next Year
$118.57
$239.71
P/E Ratio
N/A
N/A
Revenue Growth
N/A
128.21
52 Week Low
$1.19
$3.04
52 Week High
$3.59
$5.10

Technical Indicators

Market Signals
Indicator
NFGC
ABUS
Relative Strength Index (RSI) 54.37 48.45
Support Level $1.85 $4.17
Resistance Level $2.34 $4.64
Average True Range (ATR) 0.12 0.17
MACD 0.02 0.01
Stochastic Oscillator 67.78 50.81

Price Performance

Historical Comparison
NFGC
ABUS

About NFGC New Found Gold Corp

New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Company's exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: